CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 23 enrolled
Drug / intervention
Ertapenemdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00535652
NCT00535652Phase 4Completed
CompareCT.gov

Konzentrationen Von Ertapenem in Kolorektalem Gewebe

University of Ulm·interventional·Posted Sep 26, 2007·Updated Feb 10, 2017

In Brief

A Phase 4 clinical trial evaluating Ertapenem for Diverticulosis, Colonic and 2 related conditions. Completed, enrolled 23 participants across 1 site.

Detailed Summary

The purpose of this study is to determine the tissue kinetics of ertapenem in colonic tissue from three hours up to six hours (25% of dosing interval) after administration of ertapenem.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiverticulosis, Colonic, Rectal Neoplasms, Colonic Neoplasms
CountriesGermany
Collaborators--

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 26, 2007
Enrollment StartSep 1, 2007
Primary CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 18.8 years ago

Interventions

Ertapenemdrug

powder for infusion, 1 gram I.V., single dose over 30 min.